

Kathryn S Torok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3191080/publications.pdf>

Version: 2024-02-01

68
papers

1,665
citations

361413

20
h-index

315739

38
g-index

69
all docs

69
docs citations

69
times ranked

1126
citing authors

#	ARTICLE	IF	CITATIONS
1	Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2022, 74, 364-370.	3.4	13
2	Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort. <i>Arthritis Care and Research</i> , 2022, 74, 1575-1584.	3.4	13
3	Revealing novel, latent subsets of patients with morphea through principal component analysis. <i>British Journal of Dermatology</i> , 2022, 186, 193-195.	1.5	2
4	Evaluation and Treatment of Pediatric Localized Scleroderma: Pearls and Updates. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 1-20.	1.4	1
5	Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma. <i>Rheumatology</i> , 2021, 60, 5724-5733.	1.9	16
6	An Evaluation of the Performance of Current Morphea Subtype Classifications. <i>JAMA Dermatology</i> , 2021, 157, 399.	4.1	15
7	Genetic Signatures From RNA Sequencing of Pediatric Localized Scleroderma Skin. <i>Frontiers in Pediatrics</i> , 2021, 9, 669116.	1.9	15
8	DNA methylation patterns in juvenile systemic sclerosis and localized scleroderma. <i>Clinical Immunology</i> , 2021, 228, 108756.	3.2	4
9	Transcriptomic Evaluation of Juvenile Localized Scleroderma Skin With Histologic and Clinical Correlation. <i>Arthritis and Rheumatology</i> , 2021, 73, 1921-1930.	5.6	9
10	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 757-780.	1.9	5
11	Review for best practice in clinical rheumatology juvenile systemic sclerosis “ Updates and practice points. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101688.	3.3	6
12	Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma. <i>Rheumatology</i> , 2021, 60, 3817-3825.	1.9	16
13	An erythematous patch on the ear and face of a young boy. <i>Pediatric Dermatology</i> , 2021, 38, e45-e47.	0.9	0
14	A novel patient-reported outcome for paediatric localized scleroderma: a qualitative assessment of content validity. <i>British Journal of Dermatology</i> , 2020, 182, 625-635.	1.5	11
15	Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma. <i>Journal of Rheumatology</i> , 2020, 47, 1242-1252.	2.0	21
16	Single-cell transcriptome conservation in a comparative analysis of fresh and cryopreserved human skin tissue: pilot in localized scleroderma. <i>Arthritis Research and Therapy</i> , 2020, 22, 263.	3.5	21
17	The importance of development standards for anchoring vignettes: an illustrative example from pediatric localized scleroderma quality of life. <i>Quality of Life Research</i> , 2020, 29, 3263-3272.	3.1	5
18	Unilateral Neuroimaging Findings in Pediatric Craniofacial Scleroderma: Parry-Romberg Syndrome and En Coup de Sabre. <i>Journal of Child Neurology</i> , 2020, 35, 753-762.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Assigning values to the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) score indicating degree of severity and responsiveness: fostering practical use in clinic and therapeutic studies for morphea/localized scleroderma. <i>British Journal of Dermatology</i> , 2020, 182, 272-273.	1.5	3
20	Exploring the impact of paediatric localized scleroderma on health-related quality of life: focus groups with youth and caregivers. <i>British Journal of Dermatology</i> , 2020, 183, 692-701.	1.5	15
21	Combined Assay for Detecting Autoantibodies to Nucleic Acids and Apolipoprotein H in Patients with Systemic Lupus Erythematosus. <i>Methods in Molecular Biology</i> , 2020, 2063, 57-71.	0.9	3
22	Linear Scleroderma of the Head - Updates in management of Parry Romberg Syndrome and En coup de sabre: A rapid scoping review across subspecialties. <i>European Journal of Rheumatology</i> , 2020, 7, S48-S57.	0.6	12
23	Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 49-61.	1.7	20
24	Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. <i>Pediatric Rheumatology</i> , 2019, 17, 43.	2.1	10
25	Immunopathogenesis of Juvenile Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1352.	4.8	23
26	Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. <i>ACR Open Rheumatology</i> , 2019, 1, 119-124.	2.1	36
27	Autoantibodies in Morphea: An Update. <i>Frontiers in Immunology</i> , 2019, 10, 1487.	4.8	29
28	Immunopathogenesis of Pediatric Localized Scleroderma. <i>Frontiers in Immunology</i> , 2019, 10, 908.	4.8	62
29	Efficacy and cost savings with the use of a minimal sedation / anxiolysis protocol for intra-articular corticosteroid injections in children with juvenile idiopathic arthritis: a retrospective review of prospectively collected data. <i>Pediatric Rheumatology</i> , 2019, 17, 11.	2.1	3
30	AB0967â€¦IS THERE A DIFFERENCE IN PRESENTATION OF FEMALE AND MALE PATIENTS WITH JUVENILE SYSTEMIC SCLERODERMA. AN UPDATE FROM THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM. , 2019, , .		0
31	SAT0479â€¦UPDATE FROM THE JUVENILE SCLERODERMA INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM. , 2019, , .		0
32	SAT0478â€¦AFTER 24 MONTHS OBSERVATION PERIOD THE PATIENTS RELATED OUTCOMES IMPROVE SIGNIFICANTLY IN THE JUVENILE SCLERODERMA INCEPTIONS COHORT. WWW.JUVENILE-SCLERODERMA.COM. , 2019, , .		0
33	AB0966â€¦PROPOSAL OF OUTCOME MEASURES TO BE USED ON A 12-MONTH OPEN LABEL DRUG TRIAL IN JUVENILE SYSTEMIC SCLEROSIS. RESULTS OF THE 3RD CONSENSUS MEETING IN HAMBURG DECEMBER 2018. , 2019, , .		0
34	Identifying the Signature Immune Phenotypes Present in Pediatric Localized Scleroderma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 715-718.	0.7	25
35	Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. <i>British Journal of Dermatology</i> , 2019, 180, 1183-1189.	1.5	35
36	Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. <i>Arthritis Care and Research</i> , 2018, 70, 1806-1813.	3.4	26

#	ARTICLE	IF	CITATIONS
37	Chronic Recurrent Multifocal Osteomyelitis of the Mandible: A Diagnostic Challenge. <i>Plastic and Reconstructive Surgery</i> , 2018, 142, 186-192.	1.4	8
38	Psychometric properties of the Children's Dermatology Life Quality Index in pediatric localized scleroderma. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 175-181.	1.7	6
39	New Features for Measuring Disease Activity in Pediatric Localized Scleroderma. <i>Journal of Rheumatology</i> , 2018, 45, 1680-1688.	2.0	24
40	Detection of autoimmune antibodies in localized scleroderma by synthetic oligonucleotide antigens. <i>PLoS ONE</i> , 2018, 13, e0195381.	2.5	12
41	Development of minimum standards of care for juvenile localized scleroderma. <i>European Journal of Pediatrics</i> , 2018, 177, 961-977.	2.7	45
42	Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma. <i>Arthritis Care and Research</i> , 2017, 69, 1082-1087.	3.4	37
43	SAT0256...Juvenile Systemic Sclerosis Cohort within The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry: Baseline and Follow Up Characteristics. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 761.2-761.	0.9	1
44	Brief Report: HLA*DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2772-2777.	5.6	15
45	SAT0257...Update on The Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of The First 74 Patients at First Assessment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 761.3-762.	0.9	0
46	THU0229...Is There A Difference in The Presentation of Diffuse and Limited Subtype in Childhood? Results from The Juvenile Scleroderma Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 271.1-271.	0.9	0
47	Durometry as an outcome measure in juvenile localized scleroderma. <i>British Journal of Dermatology</i> , 2016, 174, 228-230.	1.5	10
48	THU0230...Is There A Difference in The Presentation of Male and Female Patients with Juvenile Systemic Sclerosis? Results from The Juvenile Scleroderma Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 271.2-271.	0.9	0
49	Emotional and mental health impact of morphea demonstrated in adults. <i>British Journal of Dermatology</i> , 2015, 172, 1188-1190.	1.5	0
50	A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. <i>Open Rheumatology Journal</i> , 2015, 9, 30-35.	0.2	27
51	Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 284-293.	3.4	59
52	A28: Description of the Juvenile Localized Scleroderma Subgroup of the CARRA Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, S43-S44.	5.6	18
53	A48: Durometer Measures Discriminate Affected versus Normal Skin in Pediatric Localized Scleroderma. <i>Arthritis and Rheumatology</i> , 2014, 66, S72-S73.	5.6	6
54	Coronary artery involvement in pediatric Takayasu's arteritis: Case report and literature review. <i>Pediatric Rheumatology</i> , 2013, 11, 4.	2.1	15

#	ARTICLE	IF	CITATIONS
55	The Localized Scleroderma Cutaneous Assessment Tool: Responsiveness to change in a pediatric clinical population. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 214-220.	1.2	91
56	Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. <i>Arthritis Research and Therapy</i> , 2013, 15, R188.	3.5	40
57	Methotrexate and Corticosteroids in the Treatment of Localized Scleroderma: A Standardized Prospective Longitudinal Single-center Study. <i>Journal of Rheumatology</i> , 2012, 39, 286-294.	2.0	91
58	Pediatric Scleroderma: Systemic or Localized Forms. <i>Pediatric Clinics of North America</i> , 2012, 59, 381-405.	1.8	77
59	Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized scleroderma. <i>Arthritis Care and Research</i> , 2012, 64, 1175-1185.	3.4	137
60	Cytokine profiles in localized scleroderma and relationship to clinical features. <i>Cytokine</i> , 2011, 55, 157-164.	3.2	98
61	Canakinumab for the treatment of adult and pediatric cryopyrin-associated periodic syndromes (CAPS). <i>Drug Development Research</i> , 2011, 72, 553-560.	2.9	0
62	Hypocomplementemia Associated with Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still's Disease: 3 Cases: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 396-397.	2.0	16
63	Autoimmune thyroiditis in antinuclear antibody positive children without rheumatologic disease. <i>Pediatric Rheumatology</i> , 2010, 8, 15.	2.1	13
64	Improvement in medication education in a pediatric subspecialty practice. <i>Pediatric Rheumatology</i> , 2010, 8, 25.	2.1	1
65	Development and initial validation of the Localized Scleroderma Skin Damage Index and Physician Global Assessment of disease Damage: a proof-of-concept study. <i>Rheumatology</i> , 2010, 49, 373-381.	1.9	171
66	Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S28-36.	0.8	14
67	The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures. <i>Journal of Rheumatology</i> , 2009, 36, 2819-2829.	2.0	147
68	Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma. <i>AMRC Open Research</i> , 0, 3, 20.	1.7	2